Wire News
Targacept's P.2b depression study succeeds: 6-point difference on HAM-D
Targacept Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics, today announced the presentation of data from its recently completed Phase 2b clinical trial of TC-5214 as an augmentation treatment in s ...
Source:
DISCLAIMER
Monday, October 26, 2009